Press release
Malignant Pleural Mesothelioma Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Malignant Pleural Mesothelioma Overview
Malignant pleura Mesothelioma (MPM) is an aggressive cancer arising from the mesothelial cells of the pleura. The pleura is thin cellular lining than envelops both the lung (termed the "visceral" pleura) and chest wall (the "parietal" pleura), as well as the diaphragm, and the heart and major blood vessels in the central portion of the chest.
"Malignant Pleural Mesothelioma Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Malignant Pleural Mesothelioma Market.
The Malignant Pleural Mesothelioma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Malignant Pleural Mesothelioma Pipeline Report: https://www.delveinsight.com/report-store/malignant-pleural-mesothelioma-mpm-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Malignant Pleural Mesothelioma treatment therapies with a considerable amount of success over the years. Malignant Pleural Mesothelioma Key players such as - Inhibrx, Nurix Therapeutics, Atara Biotherapeutics, TCR2 Therapeutics, RS Oncology, Sanofi, MomotaroGene, AstraZeneca, Merck & Co, and others, are developing therapies for the Malignant Pleural Mesothelioma treatment
• Malignant Pleural Mesothelioma Emerging therapies such as - INBRX-109, NX-1607, ATA2271, TC-510, RSO-021, SAR-444245, MTG201, Durvalumab, Pembrolizumab, and others are expected to have a significant impact on the Malignant Pleural Mesothelioma market in the coming years.
• In March 2021, Merck & Co initiated a Pembrolizumab plus Lenvatinib in second line andthird line Malignant Pleural mesothelioma patients (PEMMELA
Route of Administration
Malignant Pleural Mesothelioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type
Molecule Type
Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Malignant Pleural Mesothelioma Pipeline Therapeutics Assessment
• Malignant Pleural Mesothelioma Assessment by Product Type
• Malignant Pleural Mesothelioma By Stage and Product Type
• Malignant Pleural Mesothelioma Assessment by Route of Administration
• Malignant Pleural Mesothelioma By Stage and Route of Administration
• Malignant Pleural Mesothelioma Assessment by Molecule Type
• Malignant Pleural Mesothelioma by Stage and Molecule Type
DelveInsight's Malignant Pleural Mesothelioma Report covers around 20+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Some of the key companies in the Malignant Pleural Mesothelioma Therapeutics Market include:
Key companies developing therapies for Malignant Pleural Mesothelioma are - Amphera BV, Polaris Pharmaceuticals, Sellas Life Sciences Group, Momotaro-Gene, PharmaMar, AstraZeneca, Targovax, TCR2 Therapeutics, Hoffmann-La Roche, Novartis, MolMed, Ys Therapeutics, Merck Sharp & Dohme Corp., Kissei Pharmaceutical Co., Ltd., NovoCure Ltd, AGC Biologics S.p.A, Aduro Biotech, Inc, Bristol-Myers Squibb, Novotech (Australia) Pty Limited, Kyorin Pharmaceuticals, ACADIA Pharmaceuticals, and others.
Emerging Malignant Pleural Mesothelioma Drugs Under Different Phases of Clinical Development Include:
• INBRX-109: Inhibrx
• NX-1607: Nurix Therapeutics
• ATA2271: Atara Biotherapeutics
• TC-510: TCR2 Therapeutics
• RSO-021: RS Oncology
• SAR-444245: Sanofi
• MTG201: MomotaroGene
• Durvalumab: AstraZeneca
• Pembrolizumab: Merck & Co
Get a Free Sample PDF Report to know more about Malignant Pleural Mesothelioma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-mpm-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Malignant Pleural Mesothelioma Pipeline Analysis:
The Malignant Pleural Mesothelioma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Malignant Pleural Mesothelioma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Malignant Pleural Mesothelioma Treatment.
• Malignant Pleural Mesothelioma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Malignant Pleural Mesothelioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Malignant Pleural Mesothelioma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Malignant Pleural Mesothelioma product details are provided in the report. Download the Malignant Pleural Mesothelioma pipeline report to learn more about the emerging Malignant Pleural Mesothelioma therapies at:
https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-mpm-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Malignant Pleural Mesothelioma Pipeline Market Drivers
• Increased adoption of combination therapies
Malignant Pleural Mesothelioma Pipeline Market Barriers
• Treatment of unresectable malignant pleural mesothelioma (MPM) remains a challenging problem
• High Cost of Treatment
Scope of Malignant Pleural Mesothelioma Pipeline Drug Insight
• Coverage: Global
• Key Malignant Pleural Mesothelioma Companies: Inhibrx, Nurix Therapeutics, Atara Biotherapeutics, TCR2 Therapeutics, RS Oncology, Sanofi, MomotaroGene, AstraZeneca, Merck & Co, and others
• Key Malignant Pleural Mesothelioma Therapies: INBRX-109, NX-1607, ATA2271, TC-510, RSO-021, SAR-444245, MTG201, Durvalumab, Pembrolizumab, and others
• Malignant Pleural Mesothelioma Therapeutic Assessment: Malignant Pleural Mesothelioma current marketed and Malignant Pleural Mesothelioma emerging therapies
• Malignant Pleural Mesothelioma Market Dynamics: Malignant Pleural Mesothelioma market drivers and Malignant Pleural Mesothelioma market barriers
Request for Sample PDF Report for Malignant Pleural Mesothelioma Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-mpm-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1 Malignant Pleural Mesothelioma Report Introduction
2 Malignant Pleural Mesothelioma Executive Summary
3 Malignant Pleural Mesothelioma Overview
4 Malignant Pleural Mesothelioma- Analytical Perspective In-depth Commercial Assessment
5 Malignant Pleural Mesothelioma Pipeline Therapeutics
6 Malignant Pleural Mesothelioma Late Stage Products (Phase II/III)
7 Malignant Pleural Mesothelioma Mid Stage Products (Phase II)
8 Malignant Pleural Mesothelioma Early Stage Products (Phase I)
9 Malignant Pleural Mesothelioma Preclinical Stage Products
10 Malignant Pleural Mesothelioma Therapeutics Assessment
11 Malignant Pleural Mesothelioma Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Malignant Pleural Mesothelioma Key Companies
14 Malignant Pleural Mesothelioma Key Products
15 Malignant Pleural Mesothelioma Unmet Needs
16 Malignant Pleural Mesothelioma Market Drivers and Barriers
17 Malignant Pleural Mesothelioma Future Perspectives and Conclusion
18 Malignant Pleural Mesothelioma Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report to know more about Malignant Pleural Mesothelioma drugs and therapies- https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-mpm-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Related Reports:
Malignant Pleural Mesothelioma Market https://www.delveinsight.com/report-store/malignant-pleural-mesothelioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Malignant Pleural Mesothelioma-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Malignant Pleural Mesothelioma Epidemiology https://www.delveinsight.com/report-store/malignant-pleural-mesothelioma-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Malignant Pleural Mesothelioma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Related Reports By DelveInsight -
Hypertrophic Scar Market
https://www.delveinsight.com/report-store/hypertrophic-scar-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Hypertrophic Scar Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypertrophic Scar, historical and forecasted epidemiology as well as the Hypertrophic Scar market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Lung Fibrosis Market https://www.delveinsight.com/report-store/lung-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Lung Fibrosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Lung Fibrosis, historical and forecasted epidemiology as well as the Lung Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Anterior Uveitis Market https://www.delveinsight.com/report-store/anterior-uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Anterior Uveitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Anterior Uveitis, historical and forecasted epidemiology as well as the Anterior Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
22q11.2 deletion syndrome Market https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "22q11.2 Deletion Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
X-Linked Retinitis Pigmentosa (XLRP) Market https://www.delveinsight.com/report-store/x-linked-retinitis-pigmentosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "X-Linked Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the X-Linked Retinitis Pigmentosa (XLRP), historical and forecasted epidemiology as well as the X-Linked Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Malignant Pleural Mesothelioma Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments here
News-ID: 2952711 • Views: …
More Releases from DelveInsight Business Research
Waldenstrom Macroglobulinemia Market Analysis 2034 - Competitive Landscape, Clin …
Waldenström macroglobulinemia (WM) is a rare, slow-developing non-Hodgkin lymphoma characterized by abnormal B-cell growth in the bone marrow and excessive production of IgM protein. In 2023, around 3,190 new cases were reported across the 7MM, with the US contributing about 40%. The disease is more common in males, and nearly half of cases occur in individuals over 65 due to genetic and age-related factors, including the MYD88 L265P mutation found…
Wilson's Disease Market Analysis 2034 - Competitive Landscape, Clinical Trials, …
DelveInsight reports that approximately 8,000 diagnosed prevalent cases of Wilson's Disease were recorded in the 7MM in 2023, with numbers projected to rise through 2034. The United States leads the market with a 2023 valuation of about USD 126 million, expected to grow at a CAGR of 13%. Current treatment mainly involves chelating agents and zinc salts, with chelating agents dominating the U.S. market at around USD 123 million. Recent…
Biktarvy Market and Sales Forecast: Strong Global Adoption, Expanding Indication …
DelveInsight, a leading business intelligence and market research firm, announced the publication of its latest report, "Biktarvy Market Insights, Sales Forecast, and Competitive Landscape - 2034." The report provides an in-depth commercial, clinical, and strategic outlook on Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide), reinforcing its continued leadership as one of the most widely prescribed HIV therapies worldwide.
As global healthcare systems increasingly adopt simplified antiretroviral regimens to improve adherence and long-term viral suppression, Biktarvy…
Global Biologics Contract Manufacturing Market to reach USD 47,494.63 million at …
According to DelveInsight's analysis, The increasing incidence of chronic conditions such as cancer, diabetes, and autoimmune diseases is driving the demand for biologic therapies, prompting pharmaceutical companies to outsource large-scale production to contract manufacturers. Additionally, the expanding pipeline of biologics-including monoclonal antibodies, vaccines, and biosimilars-necessitates adaptable manufacturing solutions to address rising market demand efficiently. Moreover, advancements in biotechnology and biomedical techniques, such as recombinant DNA technology and enhanced expression systems,…
More Releases for Malignant
Malignant Mesothelioma Market Size and Forecast
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Malignant Mesothelioma Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion.
The impact of manufacturers on the market is significant across various industries, influencing supply chains, consumer choices, and economic growth. Manufacturers are key players in…
Adult Malignant Glioma Therapeutics Market - Defying the Tumor, Empowering Survi …
Newark, New Castle, USA - new report, titled Adult Malignant Glioma Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Adult Malignant Glioma Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Adult Malignant Glioma Therapeutics market. The report offers…
Malignant Mesothelioma-Pipeline Review H2 2018
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Human Parainfluenza Virus 3 Infections-Pipeline Review, H2 2018, provides an overview of the Human Parainfluenza Virus 3 Infections (Infectious Disease) pipeline landscape.
Human parainfluenza virus 3 is a life-threatening infection that causes respiratory illnesses in infants and young children. Symptoms include fever, cough, runny nose, croup, bronchiolitis, wheezing and sore throat. Treatment includes over-the-counter medications for pain and fever.
Report Highlights
Publisher's Pharmaceutical…
Malignant Mesothelioma-Pipeline Review H2 2018
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Malignant Mesothelioma-Pipeline Review, H2 2018, provides an overview of the Malignant Mesothelioma (Oncology) pipeline landscape.
Malignant pleural mesothelioma is a rare cancer often diagnosed in people who have been exposed to high levels of asbestos. The malignancy affects the pleura, a thin membrane of lubricating cells that lines the lungs and chest wall. Peritoneal mesothelioma originates in the abdomen and as a result,…
Malignant Melanoma Drug Market Malignant Melanoma Clinical Pipeline Report
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to Malignant Melanoma
2. Malignant Melanoma Drug Mechanism of Action
3. Global Malignant Melanoma Market Analysis
3.1 Current Market Scenario
3.2 Global Malignant Melanoma Pipeline Overview
4. Global Malignant Melanoma Drug Market Dynamics
4.1 Favorable Market Parameters
4.2 Commercialization Challenges
5. Global Malignant Melanoma Drug Market Future Prospects
6. Global Malignant Melanoma Clinical Pipeline By…
Rising Number of People Diagnosed with Malignant Glioma Supports the Growth of t …
Glioma is a type of tumor that occurs in brain or spine. It is a group of brain tumor that includes oligodendrogliomas and astrocytomas. Gliomas include all types of brain tumors arising from supportive tissue of the brain. Malignant glioma is the most common type of brain tumor observed in adults globally. Collectively they contribute around 40% of the total cases diagnosed with brain tumor. In the last decade, there…
